Dexcom takes on Abbott in head-to-head glucose monitoring trial

Dexcom (NSDQ:DXCM) touted data today from a head-to-head trial comparing its G5 mobile continuous glucose monitoring system with Abbott‘s (NYSE:ABT) recently-approved FreeStyle Libre Flash glucose monitoring system.

The I-Hart study, which enrolled 40 people with Type I diabetes, found that Dexcom’s device reduced patients’ time spent in hypoglycemia by 43 minutes, while Abbott’s system increased patients’ time spent in hypoglycemia by 19 minutes.

Get the full story at our sister site, Drug Delivery Business News.

The post Dexcom takes on Abbott in head-to-head glucose monitoring trial appeared first on MassDevice.

from MassDevice http://ift.tt/2BG4x1v